#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	23804	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2153	1098.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1503	1503	C	1440	C	1335	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	44898	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3465	1287.1	0	.	n	.	0	T695C	SNP	695	695	T	995	995	C	1489	C,T	1337,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	44898	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3465	1287.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2271	2271	C	1453	C,T	1323,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	44898	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3465	1287.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2897	2897	T	1333	T,C,A	943,295,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	44898	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3465	1287.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2345	2345	A	1470	A	1338	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	3098	folP	852	852	100.0	folP.l15.c4.ctg.1	1564	196.9	1	SNP	p	R228S	1	.	.	682	684	AGC	1049	1051	AGC	339;343;342	A,G;G;C	307,1;310;306	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	8560	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3358	253.4	1	SNP	p	S91F	0	.	.	271	273	TCC	605	607	TCC	277;275;273	T;C;C	251;249;247	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	8560	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3358	253.4	1	SNP	p	D95N	0	.	.	283	285	GAC	617	619	GAC	271;272;272	G;A;C	247;246;251	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	8560	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3358	253.4	1	SNP	p	D95G	0	.	.	283	285	GAC	617	619	GAC	271;272;272	G;A;C	247;246;251	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	2432	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1324	182.6	1	SNP	p	G45D	1	.	.	133	135	GAC	452	454	GAC	318;320;320	G;A,G;C	285;285,1;292	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1158	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	1114	103.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	7474	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2971	250.0	1	SNP	p	D86N	0	.	.	256	258	GAC	640	642	GAC	277;276;281	G;A;C	250;247;253	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	7474	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2971	250.0	1	SNP	p	S87R	0	.	.	259	261	AGT	643	645	AGT	277;278;280	A,C;G;T	251,1;252;253	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	7474	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2971	250.0	1	SNP	p	S87I	0	.	.	259	261	AGT	643	645	AGT	277;278;280	A,C;G;T	251,1;252;253	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	7474	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2971	250.0	1	SNP	p	S87W	0	.	.	259	261	AGT	643	645	AGT	277;278;280	A,C;G;T	251,1;252;253	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	7474	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2971	250.0	1	SNP	p	S88P	0	.	.	262	264	TCC	646	648	TCC	281;280;280	T;C;C	254;254;254	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	6640	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2579	255.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1508	1510	GGC	299;296;292	G;G;C	263;257;258	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	5678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2372	237.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1257	1259	GCA	336;335;333	G;C;A	307;308;308	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2372	237.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1260	1262	ATC	333;336;336	A;T;C	306;305;306	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2372	237.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1272	1274	GTG	337;338;338	G;T;G	308;309;311	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2372	237.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1272	1274	GTG	337;338;338	G;T;G	308;309;311	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2372	237.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1776	1778	ACC	277;277;282	A;C;C	241;247;251	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2372	237.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1830	1832	GCG	289;290;289	G;C;G	256;233;242	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2372	237.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1830	1832	GCG	289;290;289	G;C;G	256;233;242	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2372	237.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1953	1955	GGC	239;236;237	G;G;C	210;207;210	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2372	237.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1962	1964	GGC	225;221;220	G;G;C	199;196;191	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	5678	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2372	237.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1980	1982	CCG	202;206;206	C,CGG;C,G;G	146,1;153,1;154	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	8496	ponA	2397	2397	99.96	ponA.l15.c30.ctg.1	3191	264.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3742	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1864	199.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	523	523	C	297	C	269	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	E48G	NONSYN	142	144	GAA	465	467	GGA	293;293;295	G;G;A	267;267;268	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	V75I	NONSYN	223	225	GTT	546	548	ATT	296;292;295	A;T;T	269;268;270	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	T89S	NONSYN	265	267	ACC	588	590	AGC	303;301;304	A;G;C	274;274;275	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	V98I	NONSYN	292	294	GTC	615	617	ATC	285;284;282	A,G;T;C	258,1;255;256	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	.	MULTIPLE	358	359	AA	680	681	CG	295;296	C;G	269;265	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	.	MULTIPLE	361	362	GA	683	685	CAG	299;300;299	C;A;G	269;269;267	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	N122K	NONSYN	364	366	AAC	687	689	AAA	303;304;303	A,G;A;A	276,1;278;278	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	K143E	NONSYN	427	429	AAA	750	752	GAA	305;307;311	G;A;A	267;269;272	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	V151A	NONSYN	451	453	GTA	774	776	GCA	321;320;317	G,A;C;A	281,1;281;279	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	T213S	NONSYN	637	639	ACA	960	962	TCA	317;317;317	T;C,T;A	296;296,1;294	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1080	1082	CAA	264;262;261	C,A;A;A	250,1;250;250	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	.	INDELS	760	762	ACA	1084	1088	ATCAA	262;260;262;266;266	A;T;C;A;A	250;248;250;256;255	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	.	INDELS	763	764	TG	1091	1093	AGT	261;263;263	A;G;T	251;253;254	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1098	1100	GAT	268;267;271	G;A;T	255;255;258	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1206	1208	AGT	351;345;346	A;G;T	318;313;308	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1212	1214	GAC	341;340;341	G;A;C	309;307;309	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1215	1217	TAC	340;336;339	T;A;C	308;304;308	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	1	SNP	p	G120K	1	.	.	358	360	AAG	680	682	CGG	295;296;293	C;G;G	269;265;265	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	1	SNP	p	D121N	0	.	.	361	363	GAC	683	686	CGC	299;299;298	C;G;C	269;267;272	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3704	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1506	244.0	1	SNP	p	A121D	1	.	.	361	363	GAC	683	686	CGC	299;299;298	C;G;C	269;267;272	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	15214	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4751	318.2	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1933	1935	AAT	317;314;317	A;A;T	296;294;297	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1382	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	890	152.6	1	SNP	p	V57M	1	.	.	169	171	ATG	450	452	ATG	284;287;285	A;T;G	265;267;265	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
